4 questions about travel.
TSA screening rules are only one layer. Unused syringes should be accompanied by injectable medication and declared for inspection. Screening permission does not establish that the product is lawfully prescribed or possessed.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
TSA screening guidance is not prescription or possession law. Carry the dispensing label and supporting documentation for prescribed medicine, and separately check state, airline and destination requirements.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
Check the departure, transit and destination countries’ medicine, controlled-substance, prescription, import and needle rules before travel. An airport security rule does not authorize import or possession.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
Use the exact product’s labeled temperature range and manufacturer travel instructions. Avoid direct contact with ice unless instructed, and ask the pharmacist how to handle an excursion.
Sources: Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; Preventing Unsafe Injection Practices; Unused Syringes; Egrifta SV prescribing information; FDA alerts health care providers and patients to dosing errors associated with compounded injectable semaglutide products; Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice; Unapproved Drugs; Vyleesi prescribing information
← All FAQ topics | Browse all peptides
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify